Assignee
SUPERNUS PHARMACEUTICALS INC
US·60 granted patents·54 pending applications·240 citations·filing 2003–2025
Top patents by PatentIndex Score
114 records- 0197US11634415B2Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·5 cites·29 claims
- 0296US11964951B2Process of making derivatives of substituted morpholinesSUPERNUS PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·2 cites·23 claims
- 0395US12215097B2Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2024·Granted Feb 4, 2025·1 cites·27 claims
- 0493US7910128B2Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeuticsSUPERNUS PHARMACEUTICALS INC·Filed 2004·Granted Mar 22, 2011·40 cites·27 claims
- 0593US7781448B2Once daily dosage forms of trospiumSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted Aug 24, 2010·6 cites·44 claims
- 0693US7759359B2Method of treating bladder dysfunction with once-a-day trospium salt formulationSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted Jul 20, 2010·6 cites·9 claims
- 0792US11919889B2Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Mar 5, 2024·1 cites·15 claims
- 0892US7410978B2Once daily dosage forms of trospiumSUPERNUS PHARMACEUTICALS INC·Filed 2004·Granted Aug 12, 2008·22 cites·37 claims
- 0991US7611728B2Osmotic delivery of therapeutic compounds by solubility enhancementSUPERNUS PHARMACEUTICALS INC·Filed 2003·Granted Nov 3, 2009·75 cites·17 claims
- 1091US2026008759A1Methods for producing viloxazine salts and novel polymorphs thereofSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1191US2026078098A1Process of making derivatives of substituted morpholinesSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1291US2025367208A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1390US8957206B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Feb 17, 2015·5 cites·28 claims
- 1490US7781449B2Trospium chloride treatment methodSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted Aug 24, 2010·8 cites·26 claims
- 1590US2025009752A1Method of treatment of attention deficit/hyperactivity disorder (adhd)SUPERNUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1689US9662338B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted May 30, 2017·5 cites·14 claims
- 1788US10265319B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Apr 23, 2019·4 cites·20 claims
- 1888US9358204B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Jun 7, 2016·7 cites·13 claims
- 1988US9119792B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·5 cites·20 claims
- 2087US8709478B2Once daily formulations of tetracyclinesSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Apr 29, 2014·5 cites·37 claims
- 2187US7910131B2Method of treating seizures using modified release formulations of oxcarbazepineSUPERNUS PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·4 cites·24 claims
- 2287US7722898B2Modified-release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted May 25, 2010·5 cites·20 claims
- 2387US2023381191A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2486US12569471B2Method of treatment of CNS disordersSUPERNUS PHARMACEUTICALS INC·Filed 2023·Granted Mar 10, 2026·0 cites·4 claims
- 2586US2025122180A1Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2686US2023081113A1Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2785US12121523B2Method of treatment of attention deficit/hyperactivity disorder (ADHD)SUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Oct 22, 2024·0 cites·29 claims
- 2885US9603853B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·3 cites·14 claims
- 2984US11077114B2Stabilized formulations of CNS compoundsSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Aug 3, 2021·1 cites·28 claims
- 3084US7749532B2Once daily formulations of tetracyclinesSUPERNUS PHARMACEUTICALS INC·Filed 2004·Granted Jul 6, 2010·10 cites·21 claims
- 3184US2023255892A1Osmotic drug delivery systemSUPERNUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3283US11458143B2Method of treatment of attention deficit/hyperactivity disorder (ADHD)SUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Oct 4, 2022·0 cites·9 claims
- 3383US8017149B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2008·Granted Sep 13, 2011·2 cites·22 claims
- 3482US10220042B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Mar 5, 2019·1 cites·27 claims
- 3582US9119791B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·2 cites·24 claims
- 3682US2025222004A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3782US2025228859A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3882US2025228860A1Method of treatment of attention deficit/hyperactivity disorder (adhd)SUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3981US2023295100A1Process of making derivatives of substituted morpholinesSUPERNUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4080US11896599B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2019·Granted Feb 13, 2024·0 cites·20 claims
- 4180US11166960B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2021·Granted Nov 9, 2021·0 cites·6 claims
- 4279US10201547B2Method of treatment of aggressionSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Feb 12, 2019·1 cites·6 claims
- 4379US9855278B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Jan 2, 2018·1 cites·21 claims
- 4479US9144551B2Drug formulations having reduced abuse potentialSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 29, 2015·1 cites·15 claims
- 4579US2010069390A1Method of treatment of attention deficit/hyperactivity disorder (ADHD)SUPERNUS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4678US11351120B2Use of higher doses of modified release huperzine formulationsSUPERNUS PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·3 cites·12 claims
- 4778US10058556B2Method of treatment of aggressionSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·1 cites·6 claims
- 4878US9370525B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2015·Granted Jun 21, 2016·1 cites·21 claims
- 4978US9351975B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2015·Granted May 31, 2016·1 cites·20 claims
- 5078US8821930B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Sep 2, 2014·1 cites·20 claims
Showing the top 50 of 114 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →